In our study, we aim to explore the ability of miR‐92a to regulate the progression of U14 cervical cancer cell by targeting PTEN via the MAPK/ERK signaling pathway, in order to provide a novel therapeutic target for cervical cancer. This evidence concerns the gene MAPK1 and cervical cancer.